ICU Medical (NASDAQ:ICUI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of ICU Medical (NASDAQ:ICUI) from a buy rating to a strong-buy rating in a research note released on Saturday morning.

ICUI has been the subject of a number of other research reports. Raymond James Financial reissued a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday. KeyCorp lifted their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Weiss Ratings raised ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Piper Sandler upped their target price on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Needham & Company LLC increased their target price on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $192.80.

ICU Medical Stock Performance

ICU Medical stock opened at $182.42 on Friday. ICU Medical has a 12-month low of $107.00 and a 12-month high of $192.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The company has a market capitalization of $4.56 billion, a price-to-earnings ratio of 154.59, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74. The firm’s fifty day moving average price is $152.66 and its 200 day moving average price is $141.12.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.46. The company had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the company posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts forecast that ICU Medical will post 6.51 EPS for the current fiscal year.

Insider Activity

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the transaction, the vice president owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Madison Asset Management LLC acquired a new stake in ICU Medical during the second quarter valued at approximately $2,652,000. BlackRock Inc. acquired a new position in shares of ICU Medical in the 2nd quarter worth approximately $550,250,000. Deutsche Bank AG acquired a new position in shares of ICU Medical in the 2nd quarter worth approximately $4,302,000. Bank of New York Mellon Corp bought a new stake in shares of ICU Medical in the 2nd quarter valued at approximately $26,966,000. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of ICU Medical in the 2nd quarter valued at approximately $347,000. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.